Morning Summary - May 11 2026

Research evidence excerpt

Morning Summary - May 11 2026

MORNING SUMMARY

May 11, 2026

Biotechnology: CHRS - A Coherent Strategy to Unlock Anti-Tumor Immunity Through Treg Depletion: Initiating Coverage of

Coherus Oncology with a BUY Rating and $12 PT

Biotechnology: JBIO/VERA: Remain Bullish on JBIO Ahead of JADE101 Data on June 5 and VERA Ahead of July 7 Atacicept

PDUFA; Raise JBIO PT to $32; Reiterate BUY on Both

Global Biopharmaceuticals: Daily GLP-1 Tracker: Oral Wegovy and Foundayo IQVIA Rx Tracker Up to Friday, May 8

Technology & Media: What Price Is Right? Weekly EV/Recurring Revenue Screen (2026 - Week 19)

Media, Internet & Communications Daily: MIC Ride Home: WMG Agrees to $300M Deal for Red Hot Chili Peppers Catalog

Rights - Rpt; Uber Launches New Robotaxi Public Policy Push; WBD's 'Mortal Kombat II' Eyes $40-45M Opening

Global Biopharmaceuticals: Daily GLP-1 Tracker: Oral Wegovy and Foundayo IQVIA Rx Tracker Up to Wednesday, May 6

Global Biopharmaceuticals: GLP-1 Tracker: This Week's IQVIA Rx (Week Ending May 1, 2026)

Media, Internet & Communications Daily: Daily MIC: Rupert Murdoch's NFL Blitz, League Shopping Add'l Games to Networks -

Rpts; Sony C1Q Recorded Music Revenue +23%; NCAA Tourney Expansion Yields $50M/Year in Media Rights

INITIATION OF COVERAGE

BIOTECHNOLOGY Buy

CHRS - A Coherent Strategy to Unlock Anti-Tumor Immunity Through

Treg Depletion:

Rating and $12 PT Initiating Coverage of Coherus Oncology with a BUY CHRS $1.75 Price$12.00Target

Paul Jeng, Ph.D.

617 859 4618, paul.jeng@guggenheimpartners.com Current Q Next Q Current FY Next FY

$13.6 $15.3 $65.2 $104.3Michael Schmidt, Ph.D.

617 859 4636, michael.schmidt@guggenheimpartners.com

Market Cap (M) Metric Mult Curr Yr. Mult Next Yr.

CLICK HERE TO ACCESS THIS REPORT $270 Rev($)M 4.1x 2.6x

Published on May 11, 2026